81
Participants
Start Date
January 19, 2018
Primary Completion Date
January 1, 2023
Study Completion Date
February 23, 2023
Deferiprone 600mg delayed release tablets
The active substance, Deferiprone, is a member of the 3-hydroxypyrid-4-one class of iron chelators, which have a high affinity for ferric iron, binding it in a 3:1 (Deferiprone:iron) molar ratio.
Placebo Oral Tablet
The placebo will mimic the Deferiprone arm in every way, except the placebo will not include the active ingredient
KaRa Institute of Neurological Diseases, Macquarie Park
Hunter New England Local Health District, Waratah
Alfred Hospital, Melbourne
Royal Melbourne Hospital, Parkville
Austin Health, Heidelberg
Box Hill Hospital, Box Hill
NeuroCentrix, Noble Park
Australian Alzheimer's Research Foundation, Nedlands
Lead Sponsor
The Florey Institute of Neuroscience and Mental Health
OTHER
Neuroscience Trials Australia
OTHER